Bartter syndrome

Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on:

Monday, May 3, 2021

Medical specialties, Clinical medicine, Medicine, Nephrology, Gastrointestinal tract disorders, Hypokalemia, Potassium, Peptic ulcer disease, Stress ulcer, Bartter syndrome

Monitor patients for effects of HPA axis suppression after stopping treatment\nCushing\'s syndrome may occur during therapy but generally resolves after therapy is stopped.

Key Points:

Monitor patients for effects of HPA axis suppression after stopping treatment\nCushing\'s syndrome may occur during therapy but generally resolves after therapy is stopped.
Monitor patients for signs and symptoms\nActhar can cause elevation of blood pressure, salt and water retention, and hypokalemia.
Monitor blood pressure and sodium and potassium levels\nActhar often acts by masking symptoms of other diseases/disorders.
Monitor patients carefully during and for a period following discontinuation of therapy\nActhar can cause gastrointestinal (GI) bleeding and gastric ulcer.